TEG001

**TEG001** is an autologous cell therapy product consisting of αβ T cells genetically engineered to express a high-affinity Vγ9Vδ2 T-cell receptor (TCR) clone 5, enabling tumor recognition through sensing of cancer-mediated metabolic changes, particularly via phosphoantigens and BTN3A1 (CD277).[1][2][7][9] Developed as an academic GMP-grade product primarily by researchers at institutions like UMC Utrecht, it demonstrates broad reactivity against hematological malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and multiple myeloma (MM) in preclinical models and early clinical data, with persistence up to 56 days post-infusion and preliminary efficacy signals such as complete remission in AML patients.[1][5][9] It is administered intravenously following lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and pamidronate to enhance activity, in a phase I dose-escalation trial (NL6357/NTR6541) assessing safety and tolerability.[1][5]